Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Penumbra (NYSE: PEN) reported second-quarter 2026 revenue of $390.0 million, up 14.9% year over year. Thrombectomy revenue was $259.0 million (+12.5%), while embolization and access revenue reached $131.1 million (+20.0%). U.S. revenue grew 17.1% to $305.4 million; international revenue increased 7.6% to $84.6 million.
Gross margin was 67.9%, up 1.9 percentage points. Operating expenses were $223.9 million, including $6.9 million of acquisition-related costs tied to the pending acquisition by Boston Scientific (NYSE: BSX). Income from operations was $41.0 million, and net income was $34.8 million, or $0.88 diluted EPS. Penumbra will not provide 2026 guidance or host a Q2 earnings call due to the pending transaction.
Penumbra (NYSE:PEN) reported top-line results from THUNDER, a U.S. Investigational Device Exemption study evaluating its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system in acute ischemic stroke patients with emergent large vessel occlusion. The single-arm, prospective, multicenter trial enrolled 216 patients across 29 U.S. centers with core-lab adjudication.
THUNDER met its predefined performance goal, with 87.5% of cases achieving successful reperfusion (mTICI 2b-3). Post-THUNDERBOLT, 70.4% reached mTICI 2c-3, first-pass mTICI 2b-3 was 64.8%, median time-to-revascularization was 20 minutes, and complete clot ingestion was 83%. Device/procedure-related serious adverse events occurred in 2.8%, symptomatic intracranial hemorrhage in 0.9%, and 90-day all-cause mortality in 11.7%. Penumbra said THUNDERBOLT, the first and only CAVT device for stroke, has recently received U.S. FDA clearance and CE Mark.
Penumbra (NYSE:PEN) enrolled the first patient in FORWARD, an international, real‑world, prospective multi-center study evaluating mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT) and modulated aspiration, for distal acute ischemic stroke.
The study will enroll up to 250 patients at about 40 sites and assess Penumbra’s RED reperfusion catheter portfolio, including the THUNDERBOLT CAVT platform, which has CE Mark and FDA clearance.
Penumbra (NYSE:PEN) received CE Mark in Europe for its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke, following recent FDA clearance in the U.S.
THUNDERBOLT, powered by the Penumbra ENGINE, introduces modulated aspiration and is described as the only CAVT device available for stroke treatment in Europe and the U.S.
Penumbra (NYSE:PEN) received U.S. FDA clearance for THUNDERBOLT, a computer assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke. The platform delivers modulated aspiration to detect, fatigue and ingest clot at the occlusion, aiming for faster, more complete clot removal.
According to Penumbra, THUNDERBOLT is the first and only CAVT device cleared for stroke treatment in the U.S. and will be packaged with selected RED aspiration catheters.
Penumbra (NYSE: PEN) reported Q1 2026 revenue of $374.8 million, up 15.6% year-over-year, with thrombectomy revenue $253.9 million (+12.1%) and embolization & access $120.8 million (+23.8%). Gross margin was 67.6%. Operating expenses were $215.2 million (R&D $22.4M; SG&A $192.8M, including $9.4M acquisition-related expenses). Income from operations was $38.2 million and net income $32.6 million. Given the pending acquisition by Boston Scientific (NYSE: BSX), the company will not provide full-year 2026 guidance or host an earnings call.
Penumbra (NYSE: PEN) reported 90-day STORM-PE randomized trial results showing computer assisted vacuum thrombectomy (CAVT) plus anticoagulation produced significantly better functional outcomes versus anticoagulation alone for intermediate-high risk pulmonary embolism.
Key results: 6-minute walk 479m vs 368m (P=0.003); 94% vs 75.2% predicted walk distance (P=0.022); NYHA Class I 97% vs 76% (P=0.022). Safety through 90 days was comparable with no device-related mortality.
Penumbra (NYSE: PEN) reported fourth-quarter 2025 revenue of $385.4M (+22.1%) and full-year 2025 revenue of $1,403.7M (+17.5%). Gross margin improved to 68.0% in Q4 and 67.1% for FY2025. Income from operations was $59.2M in Q4 and $189.2M for FY2025. Net income for Q4 was $47.3M and FY net income was $177.7M. The company will not provide 2026 guidance or host an earnings call due to the proposed acquisition by Boston Scientific (NYSE: BSX).
Boston Scientific (NYSE: BSX) reported strong fourth-quarter 2025 results with Q4 net sales of $5.286 billion (+15.9% reported, +12.7% organic) and GAAP EPS of $0.45 (adjusted EPS $0.80). For full-year 2025, net sales were $20.074 billion (+19.9% reported) and adjusted EPS was $3.06. The company provided 2026 guidance of ~10.5–11.5% reported net sales growth and adjusted EPS of $3.43–3.49. Key developments include FDA/CE approvals for FARAPOINT PFA catheter, launches of SEISMIQ IVL and TheraSphere 360 clearance, enrollment and trial progress across AF, SCS and LAA closure studies, announced acquisitions of Penumbra and Valencia Technologies, and completion of the Nalu Medical acquisition.
Boston Scientific (NYSE: BSX) agreed to acquire Penumbra (NYSE: PEN) in a cash-and-stock deal valuing Penumbra at $374 per share, implying an enterprise value of about $14.5 billion. Consideration is ~73% cash and ~27% stock, with a 3.8721 BSX share election per PEN share. Penumbra expects 2025 reported revenue of ~$1.4 billion (growth ~17.3%–17.5%) and Q4 growth ~21.4%–22.0%. Boston Scientific plans to finance roughly $11 billion of the cash portion with cash on hand and new debt. The deal is expected to close in 2026, subject to approvals, and to be mildly dilutive to adjusted EPS by $0.06–0.08 in year one, turning neutral/acc-retive thereafter.